Directorate Change

RNS Number : 8059M

Advanced Oncotherapy PLC

30 August 2013

 



30 August 2013

ADVANCED ONCOTHERAPY PLC

("Advanced Oncotherapy" or "the Company")

Board Change

Advanced Oncotherapy announces that Non-Executive Director Trevor Brown has resigned from the Board for health reasons.  Trevor became a director in June 2012 and has been, and remains, a significant investor in the Company and major supporter of its new cancer services strategy.

Advanced Oncotherapy's CEO, Dr Mike Sinclair, said, "Trevor was an early supporter of our change of strategy to become a cancer treatment services business.  We benefited both from his advice during a time of transition and his investment in the Company.  On behalf of the Board and all of our shareholders, I thank him for his involvement. We wish him a speedy return to good health."

Trevor Brown added, "I have enjoyed being a director of Advanced Oncotherapy and participating in the design and formulation of a strategy that I believe will yield substantial returns for shareholders.  I remain a committed supporter of, and shareholder in, the Company and look forward to its continuing development and growth."

For further information, please visit www.advancedoncotherapy.com or contact:

Michael Sinclair, Chief Executive	Sandy Jamieson	Jon Levinson/ Lucy Williams	Simon Hudson
Advanced Oncotherapy Plc	Libertas Capital Corporate Finance Ltd	Peterhouse Corporate Finance	Tavistock Communications
	(NOMAD & Joint Broker)	(Joint Broker)	(Financial PR & IR)
[phone]	[phone]	[phone]	[phone]

About Advanced Oncotherapy Plc  

1.   AVO is a provider of radiotherapy services that harnesses the best in modern technology.  As a result, we offer cancer patients affordable access to innovative treatments with proven better health outcomes.

2.   AVO's acquisition of ADAM, a company spin off from CERN (The Large Hadron Collider), focuses on the development of a proprietary radiation technology called LIGHT.  This technology offers patients and providers the benefits of proton beam therapy at significantly reduced capital and running costs.

3.   AVO's subsidiary company, Oncotherapy Resources Ltd, offers an exclusive mobile service for intraoperative radiotherapy (SD-IORT).  This form of radiotherapy is used in a variety of cancers, notably breast cancer, and offers a convenient, safe and effective alternative for the patient.  It is currently available in the UK through BMI, Spire and other hospitals.

-ends-

 

END

 

 

BOAPGUPURUPWGMB